Building New Pharmaceutical Capabilities in Central Asia

在中亚建立新的制药能力

• 批准号: 6719914
• 负责人: ILYA RASKIN
• 金额: $ 69.2万
• 依托单位: RUTGERS, THE STATE UNIV OF N.J.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-26 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6719914
• 关键词: Asia; Commonwealth of Independent States; Fungi; biological products; cooperative study; drug discovery /isolation; drug screening /evaluation; international cooperation; medicinal plants; molecular biology information system; plant extracts; prokaryote

DESCRIPTION (provided by applicant): The Central Asia ICBG program will facilitate the development of the natural product-based pharmaceutical capabilities in Uzbekistan and Kyrgyzstan while encouraging biodiversity conservation and exploration, building research and economic capacity, developing ecologically-sustainable harvesting means and enhancing training and international cooperation. Uzbekistan and Kyrgyzstan possess diverse and largely unexplored biodiversity spread over a wide range of climatic zones. The program will integrate wide-ranging, state-of-the art, multiple-target screens performed by five separate groups with powerful structural and analytical approaches designed to characterize and develop therapeutic agents produced by plants, fungi and prokaryotes from Central Asia. The program will build upon a well-developed, longstanding cooperation between the scientists in the participating countries and Rutgers University, which is supported by comprehensive legal agreements. Human diseases relevant to this region will be purposely targeted, involvement of the local scientists actively encouraged and the ethnobiological knowledge upheld. Care will be taken to assure equitable benefit sharing and biodiversity treaties compliance. The screens associated with the proposed ICBG program will encompass 10 major therapeutic areas and close to 60 specific disease-related human targets and pathogenic microorganisms. The program will generate 108,000 prokaryotic, 10,260 plant and 6,000 fungal samples for the primary phase of these screens. A comprehensive training and bioinformatics initiative, made possible through major matching funds from Rutgers University and University of Illinois, will strengthen the research and development component of the program and further increase its impact on biodiversity preservation and inventory.

中亚ICBG计划将促进乌兹别克斯坦和吉尔吉斯斯坦基于天然产物的制药能力的发展，同时鼓励生物多样性保护和探索，建立研究和经济能力，开发生态可持续的收获手段，加强培训和国际合作。乌兹别克斯坦和吉尔吉斯斯坦拥有分布在各种气候带的多样性和基本上未开发的生物多样性。该计划将整合由五个独立小组进行的广泛的，最先进的，多靶点筛选，具有强大的结构和分析方法，旨在表征和开发由中亚植物，真菌和原核生物产生的治疗剂。该计划将建立在参与国科学家与罗格斯大学之间的长期合作基础上，该合作得到全面的法律的协议的支持。与该地区有关的人类疾病将有目的地作为目标，积极鼓励当地科学家的参与，并维护民族生物学知识。将注意确保公平的利益分享和生物多样性条约的遵守。与拟议的ICBG计划相关的筛选将涵盖10个主要治疗领域和近60种特定疾病相关的人类靶点和病原微生物。该计划将为这些筛选的初级阶段产生108，000个原核生物，10，260个植物和6，000个真菌样品。通过罗格斯大学和伊利诺伊大学的主要配套资金，一项全面的培训和生物信息学倡议将加强该方案的研究和开发部分，并进一步增加其对生物多样性保护和库存的影响。